ArticleDermatology (Basel, Switzerland)2026
Patients' Preference Regarding Patient-Reported Outcome Measures for Hidradenitis Suppurativa: A Cross-Sectional Multicenter Study.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOver the last decade, research interest in hidradenitis suppurativa (HS) has grown exponentially, resulting in a need for accurate outcome measures. However, subjective outcome measures included in research have not always been those that patients regard as most important or relevant. Therefore, this manuscript evaluates the preference of patients concerning three different patient-reported outcome measures (PROMs), the DLQI, HiSQOL, and Skindex-17.
methodsThis cross-sectional, multicenter study in the Netherlands included HS patients who completed the PROMs, each followed by the QQ-10 questionnaire. Their preference regarding these PROMs was evaluated using value and burden scores of the QQ-10 questionnaire, a ranking system, and open-end responses.
resultsA total of 200 patients were included in the study. The QQ-10 value scores for the DLQI, HiSQOL, and Skindex-17 were 66.3%, 67.1%, and 69.2%, respectively. The HiSQOL and Skindex-17 had a similar mean burden score of 23.8%, while the DLQI had a burden score of 24.4%. The Skindex-17 was ranked first by 41.5% of patients, followed by the HiSQOL (31.5%) and DLQI (27%). The Skindex-17 received the most negative feedback (85 comments), followed by the DLQI (84 comments), with both questionnaires receiving criticism primarily focused on their content. The HiSQOL received 57 comments, mainly concerning its design.
conclusionPatients did not demonstrate a clear preference among the three PROMs based on value and burden scores. However, qualitative feedback from open-ended responses suggests that the HiSQOL may be preferable, given its inclusion of HS-specific symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.